Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to assess the safety of administering rhBMP-2/CPM as an adjuvant to internal fixation in subjects with fractures of the proximal femur.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
NCT07024095 · Osteoporotic Vertebral Compression Fractures, Restrictive Pulmonary Disorders, and more
NCT07538700 · Proximal Humeral Fractures
NCT07520851 · Elbow Fractures
NCT07217626 · Lower Extremity Fracture, Surgical Fracture Repair, and more
NCT07357493 · Metacarpal Shaft Fractures
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
New Haven, Connecticut
Pfizer Investigational Site
Clearwater, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions